15 news items
Actinium Pharmaceuticals (NYSE: ATNM): A Prime Target in a Wave of Radiopharmaceutical Mergers and Acquisitions
ABBV
ATNM
AZN
8 May 24
or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content
Ligand Reports First Quarter 2024 Financial Results
AMGN
CASI
JAZZ
7 May 24
equity investments in public companies, excess tax benefit from share-based compensation, income tax effect of adjusted reconciling items and others
Market Analysis: Merck & Co And Competitors In Pharmaceuticals Industry
MRK
7 May 24
.
The company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $6.96 Billion, which
Merck Announces First-Quarter 2024 Financial Results
MRK
25 Apr 24
expense in 2024.
The effective tax rate was 15.9% for the first quarter of 2024 (which includes a 1.6
Understanding Merck & Co's Position In Pharmaceuticals Industry Compared To Competitors
MRK
23 Apr 24
to various factors.
Compared to its industry, the company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization
a068ezm0f7feyr702u94omw9qoykrcsm1g6902
ABBV
ATNM
AZN
22 Apr 24
informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article constitutes an offer
cfresi5tsv0dh8nd0ag35waqsislky8xv4qa9oo8b6sqt75ul
ABBV
ATNM
AZN
19 Apr 24
a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice. No content in this article
kljd9b7yegayiixjul7nyzbu0vcx256w599t
MRK
MRNA
11 Apr 24
, aimed at finalizing the deal were in vain. Despite tax breaks and reduced investment requirements from the Kenyan government, Moderna has stalled
z3o77ivwi8q685y h2bbjw2jjizs1r
MRK
8 Apr 24
potential inefficiency in utilizing equity to generate profits.
With lower Earnings Before Interest, Taxes, Depreciation, and Amortization
do85qrbiqfatajb1x hk8icnsxg9bakgrivm
ABBV
ANIX
BIIB
20 Mar 24
a recommendation to buy or sell a security. It is solely informational, and you should not construe it as legal, tax, investment, financial, or other advice
0qr2dkjp9z
MRK
13 Mar 24
.
The company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) of $-770 Million, which is -0.03x
vqnt5dj8jyjgj05as9b
HARP
MRK
11 Mar 24
outstanding shares of Harpoon. As previously disclosed, this transaction is being accounted for as an asset acquisition. Merck is recording a non-tax
qz3ya0r8zt ldq5z5nq7y5js4axocz7vqeep
MRK
28 Feb 24
that the company exhibits potential inefficiency in utilizing equity to generate profits.
With lower Earnings Before Interest, Taxes
i0x8sh87m1vb8 3i5bmp5nojt6k5bnf2c
ALDX
LGND
MRK
27 Feb 24
compensation expense and a $24.8 million deferred tax asset valuation allowance during the fourth quarter of 2022, which was partially offset by a non-cash gain
bsb3 dvat
MRK
14 Feb 24
and demonstrates profitability and growth potential.
The company has lower Earnings Before Interest, Taxes, Depreciation, and Amortization
- Prev
- 1
- Next